A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in phase I clinical trials

DOI10.1080/07474946.2016.1238250zbMATH Open1358.62097OpenAlexW2554661229WikidataQ115006072 ScholiaQ115006072MaRDI QIDQ2958397FDOQ2958397

Authors: Steven B. Kim, Daniel L. Gillen 

Publication date: 1 February 2017

Published in: Sequential Analysis (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1080/07474946.2016.1238250

Recommendations

• Incorporating individual and collective ethics into phase I cancer trial designs
• Bayesian optimal designs for phase I clinical trials
• The treatment versus experimentation dilemma in dose finding studies
• A new design of the continual reassessment method
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs

zbMATH Keywords

phase I clinical trialsadaptive designindividual- and population-level ethicsmultiple Bayesian adaptive designs

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal statistical designs (62K05) Sequential statistical design (62L05) Bayesian problems; characterization of Bayes procedures (62C10)

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Design and Analysis of Phase I Clinical Trials
• Bayesian decision procedures based on logistic regression models for dose-finding studies
• Continual reassessment and related dose-finding designs
• Penalized optimal designs for dose-finding
• Bayesian optimal designs for phase I clinical trials
• Approximate dynamic programming and its applications to the design of Phase I cancer trials
• Incorporating individual and collective ethics into phase I cancer trial designs

Cited In (2)

• Incorporating individual and collective ethics into phase I cancer trial designs
• A Bayesian design for phase I cancer therapeutic vaccine trials

This page was built for publication: A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in phase I clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2958397)